Cerus Corporation

NASDAQ:CERS

Medical - Devices

Healthcare
$1.94 +2.92%

+$0.08 today

Market cap
$391.79M
Beta
1.77
P/E (TTM)
-53.8
EPS (TTM)
-$0.05
52W Low $1.15High $3.15

Volume 6.09M

Average 2.33M

CERS Deferred Revenue

Payments received for goods or services the company will deliver within the next year.

Cerus CorporationNASDAQ: CERS

Deferred Revenue · Q1 FY2026 · quarter ended Mar 2026

Deferred revenue falls 29.7% from a year ago

Deferred revenue stood at $1.72M at the end of Q1 FY2026, down 29.7% from a year earlier and up 35.1% from the prior quarter. Over 3 fiscal years it compounded at +29.3% a year.

Context

  • Deferred revenue amounted to 0.8% of total assets at the end of Q1 FY2026, down 0.4 pp from a year earlier.
  • Deferred revenue increased in 1 of the last 3 fiscal years.

What to watch

Whether deferred revenue keeps falling in the next quarterly balance sheet after a -29.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.72M+35.1% QoQ
Last fiscal yearDec 2025
$1.27M-8.9% YoY
Year agoMar 2025
$2.45M-29.7% since
Deferred Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-29.7%——
1 year-8.9%——
3-year CAGR+29.3%——
5-year CAGR——
10-year CAGR——

Deferred Revenue history

USD · from the balance sheet

Latest · FY2025
1.27M USD
Year-over-year change
-8.9%
4-year CAGR
+17.3%

Deferred Revenue vs competitors

How CERS compares with its peers on the latest reported figures

  • Peers report in different currencies, so deferred revenue is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -29.7% is the highest of 3, against a peer median of -100.0%.
  • Deferred revenue amounts to 0.8% of total assets for CERS, versus a peer median of 0.0%.
CERS Competitors
Deferred Revenue for CERS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CERSCerus CorporationMar 2026$1.72M USD-29.7%+29.3%0.8%
GRFSGrifols, S.A.Jun 2026€0 EUR—+26.7%0.0%
HAEHaemonetics CorporationJun 2026$0 USD-100.0%+11.9%0.0%
ADMAADMA Biologics, Inc.Jun 2026$0 USD-100.0%—0.0%
Peer median (excluding CERS) —-100.0%+19.3%0.0%

Competitors are the stored peer set for CERS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents48.76M35.59M11.65M20.27M19.96M
Short-term Investments80.6M66.57M54.21M60.19M62.92M
Net Receivables25.13M34.43M35.5M29.78M30.37M
Inventory26.79M29M39.87M38.15M56.1M
Other Current Assets04.56M3.22M3.64M5.03M
Total Current Assets187.1M170.14M144.44M152.02M174.38M
Property, Plant & Equipment (Net)25.18M23.48M19.35M15.54M19.33M
Goodwill1.32M1.32M1.32M1.32M1.32M
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets23.9M23.15M32.64M32.04M26.83M
Total Non-current Assets50.4M47.95M53.31M48.9M47.48M
Total Assets237.5M218.09M197.75M200.92M221.86M
Account Payables35.61M33M23.84M21.7M28.01M
Short-term Debt14.7M56.16M20M19.3M43.34M
Tax Payables00000
Deferred Revenue673K589K2M1.4M1.27M
Other Current Liabilities18.51M17.58M11.82M11.94M18.26M
Total Current Liabilities78.56M117.06M67.52M63.61M100.8M
Long-term Debt54.72M13.64M59.8M64.86M40.55M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities2.34M3.5M3.24M3.89M5.4M
Total Non-current Liabilities73.33M32.47M76.78M80.41M56.09M
Total Liabilities151.88M149.53M144.3M144.02M156.89M
Common Stock174K177K181K186K192K
Retained Earnings(964.34M)(1.01B)(1.04B)(1.07B)(1.08B)
Accumulated OCI(149K)(2.79M)(1.27M)(400K)(156K)
Other Stockholders Equity00000
Minority Interest998K952K794K751K741K
Total Equity85.62M68.56M53.44M56.9M64.97M
Total Debt87.59M87.24M96M98.1M96.95M
Net Debt38.83M51.65M84.35M77.83M76.99M

Cerus Corporation

NASDAQ:CERS

Intrinsic Alpha fair value

Locked

Current Price

$1.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.